<DOC>
	<DOCNO>NCT01832467</DOCNO>
	<brief_summary>To determine objective overall response re-treatment cetuximab-based chemotherapy patient upon disease progression observation , previously respond first-line second-line treatment cetuximab-based chemotherapy metastatic colorectal cancer ( mCRC ) , stop treatment reason disease progression .</brief_summary>
	<brief_title>Cetuximab Rechallenge Study</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Age 18 year old . Able give write informed consent . Histologically confirm colorectal adenocarcinoma : must either metastatic disease unresectable recurrent disease . KRAS mutation status primary metastastic CRC tumor must wildtype . ECOG performance status 01 study entry . Must measurable disease RECIST ( ver 1.1 ) criterion . Have progressive disease base follow criterion ( ad ) : ( ) Previously receive cetuximabbased chemotherapy first secondline treatment metastatic recurrent disease , one follow drug combination : ( ) Cetuximab , fluoropyrimidines oxaliplatin ; , ( ii ) Cetuximab , fluoropyrimidines irinotecan ; ( iii ) Cetuximab irinotecan . ( b ) Must achieve least stable disease , partial complete response treatment state ' ( ) ' . ( c ) Experienced disease progression 60 day last date administration treatment state ' ( ) ' . ( ) 'Disease progression ' define radiological clinical progression . Adequate hematologic , renal , hepatic function define : absolute neutrophil count &gt; = 1.5 x 109/L , hemoglobin &gt; = 9 g/L , platelet &gt; = 100 x 109/L , calculate creatinine clearance &gt; =55 ml/min , total bilirubin &lt; = 2 x upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) &lt; 2.5 upper limit normal &lt; = 5 x ULN presence liver metastasis . Must recover grade 01 severity , toxicity relate previous cetuximab . Disease progression firstline secondline treatment cetuximab chemotherapy combination . Patients prior cetuximab BOTH first secondline set . Previous use bevacizumab . Prior grade 3 4 hypersensitivity reaction cetuximab . Clinically significant poorly control medical illness within last 6 month may exacerbate study treatment . Estimated life expectancy le 3 month . Radiotherapy , surgery ( exclude prior diagnostic biopsy ) investigational drug 30 day enrollment . Radiotherapy pain relief allow long targeted index nonindex lesion , e.g. , bone metastasis . Known brain and/or leptomeningeal metastasis . Severe uncontrolled cardiovascular disease ( congestive heart failure NYHA III IV , unstable angina pectoris , history myocardial infarction within last twelve month , significant arrhythmias Pregnancy lactation Previous malignancy colorectal cancer last 5 year except basal cell cancer skin preinvasive cancer cervix . The nonCRC malignancy must know complete remission least 5 year prior enrollment . The presence KRAS mutation CRC tumor tissue ( ) example , patient synchronous primary CRCs different KRAS mutation status . Participants reproductive potential unwilling perform effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>cetuximab-based chemotherapy</keyword>
	<keyword>previously treat</keyword>
</DOC>